However, the presence of COPD can adversely affect anti-tumor therapy and reduce the survival benefits of patients, including limiting surgical opportunities, increasing postoperative complications, prolonged oxygen therapy and hospital stay, reducing benefits from chemotherapy and radiotherapy, lower epidermal growth factor receptor (EGFR) mutation rates, and worse efficacy after targeted therapy with EGFR-tyrosine kinase inhibitors (EGFR-TKI) [8–11]. This evidence concerns the gene EGFR and neoplasm.